1
|
Kratz JM, Mair CE, Oettl SK, Saxena P, Scheel O, Schuster D, Hering S, Rollinger JM. hERG Channel Blocking Ipecac Alkaloids Identified by Combined In Silico - In Vitro Screening. Planta Med 2016; 82:1009-1015. [PMID: 27145237 DOI: 10.1055/s-0042-105572] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Human ether-a-go-go-related gene channel blocking is associated with QT interval prolongation and increased risk of potentially fatal arrhythmias. As natural products keep increasing in popularity, there is an urgent need for studies assessing human ether-a-go-go-related gene channel-related cardiotoxic risks. We selected 49 plant species based on the results of a pharmacophore-based virtual screening campaign, in parallel with a literature data survey concerning highly consumed herbal medicines with reported cardiac liabilities. Lead-like enhanced extracts were prepared, an initial in vitro screening was performed at 100 µg/mL by voltage clamp on Xenopus oocytes, and five human ether-a-go-go-related gene channel blocking extracts were identified. In accordance to the six virtually predicted alkaloids, the root extract of Carapichea ipecacuanha inhibited human ether-a-go-go-related gene channel currents by 32.5 %. A phytochemical workflow resulted in the isolation and identification of five out of the six virtually predicted alkaloids. All isolates blocked human ether-a-go-go-related gene channel currents to different extents. The major ipecac constituents emetine (1) and cephaeline (2) showed IC50 values of 21.4 and 5.3 µM, respectively, measured by whole-cell patch clamp in HEK293 cells. This is the first report on human ether-a-go-go-related gene channel blockers from C. ipecacuanha. Its roots and rhizomes are used to produce different pharmacopeial ipecac preparations that are mainly used as emetics for poisoning treatment. Our findings raise further questions regarding the safety and over-the-counter appropriateness of these herbal products.
Collapse
Affiliation(s)
- Jadel M Kratz
- Department of Pharmacognosy, University of Vienna, Vienna, Austria
| | - Christina E Mair
- Department of Pharmacognosy, University of Vienna, Vienna, Austria
| | - Sarah K Oettl
- Institute of Pharmacy/Pharmacognosy, University of Innsbruck, Innsbruck, Austria
| | - Priyanka Saxena
- Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria
| | - Olaf Scheel
- Cytocentrics Bioscience GmbH, Rostock, Germany
| | - Daniela Schuster
- Institute of Pharmacy/Pharmaceutical Chemistry and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria
| | - Steffen Hering
- Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria
| | | |
Collapse
|
2
|
Oettl SK, Hubert J, Nuzillard JM, Stuppner H, Renault JH, Rollinger JM. Dereplication of depsides from the lichen Pseudevernia furfuracea by centrifugal partition chromatography combined to 13C nuclear magnetic resonance pattern recognition. Anal Chim Acta 2014; 846:60-7. [DOI: 10.1016/j.aca.2014.07.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Revised: 07/04/2014] [Accepted: 07/07/2014] [Indexed: 12/20/2022]
|
3
|
Oettl SK, Gerstmeier J, Khan SY, Wiechmann K, Bauer J, Atanasov AG, Malainer C, Awad EM, Uhrin P, Heiss EH, Waltenberger B, Remias D, Breuss JM, Boustie J, Dirsch VM, Stuppner H, Werz O, Rollinger JM. Imbricaric acid and perlatolic acid: multi-targeting anti-inflammatory depsides from Cetrelia monachorum. PLoS One 2013; 8:e76929. [PMID: 24130812 PMCID: PMC3793931 DOI: 10.1371/journal.pone.0076929] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2013] [Accepted: 09/04/2013] [Indexed: 11/19/2022] Open
Abstract
In vitro screening of 17 Alpine lichen species for their inhibitory activity against 5-lipoxygenase, microsomal prostaglandin E2 synthase-1 and nuclear factor kappa B revealed Cetrelia monachorum (Zahlbr.) W.L. Culb. & C.F. Culb. As conceivable source for novel anti-inflammatory compounds. Phytochemical investigation of the ethanolic crude extract resulted in the isolation and identification of 11 constituents, belonging to depsides and derivatives of orsellinic acid, olivetolic acid and olivetol. The two depsides imbricaric acid (4) and perlatolic acid (5) approved dual inhibitory activities on microsomal prostaglandin E2 synthase-1 (IC50 = 1.9 and 0.4 µM, resp.) and on 5-lipoxygenase tested in a cell-based assay (IC50 = 5.3 and 1.8 µM, resp.) and on purified enzyme (IC50 = 3.5 and 0.4 µM, resp.). Additionally, these two main constituents quantified in the extract with 15.22% (4) and 9.10% (5) showed significant inhibition of tumor necrosis factor alpha-induced nuclear factor kappa B activation in luciferase reporter cells with IC50 values of 2.0 and 7.0 µM, respectively. In a murine in vivo model of inflammation, 5 impaired the inflammatory, thioglycollate-induced recruitment of leukocytes to the peritoneum. The potent inhibitory effects on the three identified targets attest 4 and 5 a pronounced multi-target anti-inflammatory profile which warrants further investigation on their pharmacokinetics and in vivo efficacy.
Collapse
Affiliation(s)
- Sarah K. Oettl
- Institute of Pharmacy/Pharmacognosy, Center for Molecular Biosciences Innsbruck, Leopold-Franzens University of Innsbruck, Innsbruck, Austria
| | - Jana Gerstmeier
- Chair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University of Jena, Jena, Germany
| | - Shafaat Y. Khan
- Institute of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria
| | - Katja Wiechmann
- Chair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University of Jena, Jena, Germany
| | - Julia Bauer
- Department of Pharmaceutical Analytics, Pharmaceutical Institute, University Tuebingen, Tuebingen, Germany
| | | | - Clemens Malainer
- Department of Pharmacognosy, University of Vienna, Vienna, Austria
| | - Ezzat M. Awad
- Institute of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria
| | - Pavel Uhrin
- Institute of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria
| | - Elke H. Heiss
- Department of Pharmacognosy, University of Vienna, Vienna, Austria
| | - Birgit Waltenberger
- Institute of Pharmacy/Pharmacognosy, Center for Molecular Biosciences Innsbruck, Leopold-Franzens University of Innsbruck, Innsbruck, Austria
| | - Daniel Remias
- Institute of Pharmacy/Pharmacognosy, Center for Molecular Biosciences Innsbruck, Leopold-Franzens University of Innsbruck, Innsbruck, Austria
| | - Johannes M. Breuss
- Institute of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria
| | - Joel Boustie
- Institute of Chemical Sciences of Rennes, Team PNSCM, University of Rennes 1, Rennes, France
| | - Verena M. Dirsch
- Department of Pharmacognosy, University of Vienna, Vienna, Austria
| | - Hermann Stuppner
- Institute of Pharmacy/Pharmacognosy, Center for Molecular Biosciences Innsbruck, Leopold-Franzens University of Innsbruck, Innsbruck, Austria
| | - Oliver Werz
- Chair of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University of Jena, Jena, Germany
- * E-mail: (JR); (OW)
| | - Judith M. Rollinger
- Institute of Pharmacy/Pharmacognosy, Center for Molecular Biosciences Innsbruck, Leopold-Franzens University of Innsbruck, Innsbruck, Austria
- * E-mail: (JR); (OW)
| |
Collapse
|